The post-administration of GAL moderately reduced plasma [a] Cr (p < 0.05) and sharply abated other biomarkers (p < 0.001) increments to provide its effectiveness in ameliorating AKI in ZYM challenging model. This evidence concerns the gene GAL and acute kidney injury.